146 related articles for article (PubMed ID: 33563190)
1. Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans.
Sidharta PN; Fischer H; Dingemanse J
Curr Drug Metab; 2021; 22(5):399-410. PubMed ID: 33563190
[TBL] [Abstract][Full Text] [Related]
2. Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects.
Sidharta PN; Melchior M; Kankam MK; Dingemanse J
Drug Des Devel Ther; 2019; 13():949-964. PubMed ID: 30962677
[TBL] [Abstract][Full Text] [Related]
3. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans.
Bruderer S; Hopfgartner G; Seiberling M; Wank J; Sidharta PN; Treiber A; Dingemanse J
Xenobiotica; 2012 Sep; 42(9):901-10. PubMed ID: 22458347
[TBL] [Abstract][Full Text] [Related]
4. Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin.
Sidharta PN; Dingemanse J
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):995-1002. PubMed ID: 32592633
[TBL] [Abstract][Full Text] [Related]
5. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
Sidharta PN; Ulč I; Dingemanse J
Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
[TBL] [Abstract][Full Text] [Related]
6. Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects.
Sidharta PN; Dingemanse J
Eur J Drug Metab Pharmacokinet; 2020 Apr; 45(2):227-234. PubMed ID: 31773427
[TBL] [Abstract][Full Text] [Related]
7. Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian Subjects.
Fontes MSC; Dingemanse J; Sidharta PN
Clin Pharmacol Drug Dev; 2021 Jul; 10(7):718-725. PubMed ID: 33063477
[TBL] [Abstract][Full Text] [Related]
8. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.
Fontes MSC; Dingemanse J; Halabi A; Tomaszewska-Kiecana M; Sidharta PN
Sci Rep; 2022 Nov; 12(1):19067. PubMed ID: 36352054
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
[TBL] [Abstract][Full Text] [Related]
10. Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.
McCoy EK; Lisenby KM
J Cardiovasc Pharmacol; 2021 Jun; 77(6):699-706. PubMed ID: 34001723
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension.
Brussee JM; Sidharta PN; Dingemanse J; Krause A
J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):243-252. PubMed ID: 38332190
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet.
Gueneau de Mussy P; Sidharta PN; Wuerzner G; Maillard MP; Guérard N; Iglarz M; Flamion B; Dingemanse J; Burnier M
Clin Pharmacol Ther; 2021 Mar; 109(3):746-753. PubMed ID: 32897570
[TBL] [Abstract][Full Text] [Related]
13. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
Sidharta PN; van Giersbergen PL; Wolzt M; Dingemanse J
Br J Clin Pharmacol; 2014 Nov; 78(5):1035-42. PubMed ID: 24962473
[TBL] [Abstract][Full Text] [Related]
14. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.
Angeli F; Verdecchia P; Reboldi G
Cardiol Ther; 2021 Dec; 10(2):397-406. PubMed ID: 34251649
[TBL] [Abstract][Full Text] [Related]
15. Aprocitentan: A new development of resistant hypertension.
Yao Y; Fan B; Yang B; Jia Z; Li B
J Clin Hypertens (Greenwich); 2023 Jul; 25(7):587-590. PubMed ID: 37334561
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacokinetic characteristics of clazosentan, an intravenous endothelin receptor antagonist, in humans.
van Giersbergen PL; Treiber A; Dingemanse J
Int J Clin Pharmacol Ther; 2009 Mar; 47(3):169-77. PubMed ID: 19281726
[TBL] [Abstract][Full Text] [Related]
17. A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension.
Bartolucci R; Dosne AG; Csonka D; Pérez-Ruixo JJ; Magni P; Poggesi I
Clin Pharmacokinet; 2021 Dec; 60(12):1605-1619. PubMed ID: 34159557
[TBL] [Abstract][Full Text] [Related]
18. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential.
Xu J; Jiang X; Xu S
Drug Discov Today; 2023 Nov; 28(11):103788. PubMed ID: 37742911
[TBL] [Abstract][Full Text] [Related]
19. Aprocitentan and the endothelin system in resistant hypertension.
Clozel M
Can J Physiol Pharmacol; 2022 Jul; 100(7):573-583. PubMed ID: 35245103
[TBL] [Abstract][Full Text] [Related]
20. New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis.
Mahfooz K; Najeed S; Tun HN; Khamosh M; Grewal D; Hussain A; Ong K; Dharmarajan L; Vasavada A
Curr Probl Cardiol; 2023 Jul; 48(7):101686. PubMed ID: 36893968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]